|
시장보고서
상품코드
2077561
급성 허혈성 뇌졸중(AIS) 시장 : 치료법별, 유통 채널별, 지역별Acute Ischemic Stroke (AIS) Market, By Therapeutics, By Distribution Channel, By Geography |
||||||
급성 허혈성 뇌졸중(AIS) 시장은 2026년에 103억 8,000만 달러 규모에 달할 것으로 추정되며, 2033년까지 138억 4,000만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 4.2%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 103억 8,000만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 4.20% | 2033년 시장 규모 예측: | 138억 4,000만 달러 |
급성 허혈성 뇌졸중(AIS)이란 뇌의 일부로 가는 혈류가 갑자기 차단되어, 그 결과 신경 기능이 상실되는 상태를 말합니다. 이는 뇌동맥의 혈전성 또는 색전성 폐색에 의해 발생하며, 출혈성 뇌졸중보다 더 흔합니다. 증상은 뇌졸중의 중증도나 뇌 내 발생 부위에 따라 다릅니다. 증상이 전혀 나타나지 않는 사람도 있지만, 대부분의 경우 여러 증상 중 하나만 나타납니다. 그러나 대부분의 사람은 신체의 한쪽 마비, 의식 수준의 변화, 청각이나 미각의 변화, 연하 곤란, 현기증이나 균형 감각 상실, 시각 장애 등 여러 가지 증상이 동시에 나타납니다.
시장 역학
흡연은 관상동맥 질환, 고혈압, 심근경색, 뇌졸중 및 온라인 약국 등과 같은 심혈관질환의 주요 원인 중 하나입니다. 사람이 담배를 피우면, 온몸으로 공급되는 혈액이 연기에 포함된 화학제품에 의해 오염됩니다. 이러한 화학제품은 심장이나 혈관에 손상을 입혀, 미국에서 사망 원인 1위인 심혈관질환(CVD)을 유발할 가능성이 있습니다. 예를 들어, 세계보건기구(WHO)가 2021년에 발표한 주요 자료에 따르면, 담배로 인해 전 세계에서 매년 800만 명 이상이 사망하고 있습니다. 이 사망자 중 700만 명 이상은 직접적인 흡연에 기인한 것이며, 약 120만 명은 간접흡연(타는 담배 끝에서 나오는 연기와 흡연자가 내뿜는 연기가 혼합된 것)에 노출된 비흡연자에서 비롯된 것입니다. 전 세계 13억 명의 흡연자 중 80% 이상이 방글라데시, 인도, 아프가니스탄 및 온라인 약국 등이 있는 저·중소득 국가에 살고 있습니다.
본 조사의 주요 특징:
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트도 제공하고 있습니다.
- 본 조사에서는 다음의 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 시장 전략)를 바탕으로 전 세계 급성 허혈성 뇌졸중(AIS) 시장의 주요 기업 개요을 소개하고 있습니다.
- 본 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 충분한 정보를 바탕으로 의사결정을 내릴 수 있게 됩니다.
- 본 '세계 급성 허혈성 뇌졸중(AIS) 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 전 세계 급성 허혈성 뇌졸중(AIS) 시장 분석에 활용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 급성 허혈성 뇌졸중(AIS) 시장 : 치료법별, 2021-2033년
제5장 세계의 급성 허혈성 뇌졸중(AIS) 시장 : 유통 채널별, 2021-2033년
제6장 세계의 급성 허혈성 뇌졸중(AIS) 시장 : 지역별, 2021-2033년
제7장 경쟁 구도
제8장 섹션
KSM 26.07.08Acute Ischemic Stroke (AIS) Market is estimated to be valued at USD 10.38 Bn in 2026 and is expected to reach USD 13.84 Bn by 2033, growing at a compound annual growth rate (CAGR) of 4.2% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 10.38 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 4.20% | 2033 Value Projection: | USD 13.84 Bn |
Acute ischemic stroke (AIS) is defined as the sudden loss of blood flow to an area of the brain with the consequent loss of neurological function. It is caused due to thrombotic or embolic occlusion of a cerebral artery and is more common than hemorrhagic stroke. Symptoms depend on the severity of the stroke and its location in the brain. Few people have no symptoms while Online Pharmacies only have one of the numerous symptoms. However, most people experience a combination of symptoms such as paralysis on one side of the body, changes in alertness, and changes in hearing or taste, difficulty in swallowing, dizziness or loss of balance, visual disturbances, and others.
Market Dynamics
Tobacco smoking is one of the major cause of cardiovascular disease, such as coronary heart disease, high blood pressure, heart attack, stroke, and Online Pharmacies. When a person smokes a cigarette, the blood that is distributed to the rest of the body becomes contaminated with chemicals in the smoke. These chemicals can damage the heart and blood vessels, which can lead to cardiovascular disease (CVD), the leading cause of death in the U.S. For instance, key facts provided by World Health Organization (WHO) in 2021, tobacco kills more than eight million people each year, globally. More than seven million of these deaths are due to direct tobacco use, while about 1.2 million are due to non-smokers exposed to secondhand smoke (combination of smoke from the burning end of a cigarette and the smoke breathed out by smokers). More than 80% of the world's 1.3 billion tobacco users live in low- and middle-income countries such as Bangladesh, India, Afghanistan, and Online Pharmacies.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global acute ischemic stroke (AIS) market based on the following parameters - company highlights, types portfolio, key highlights, financial performance, and market strategies
- Key companies covered as a part of this study include F. Hoffmann-La Roche AG, Boehringer Ingelheim, Bayer AG, Pfizer Inc., Biogen, Daiichi Sankyo, Bristol-Myers Squibb, Johnson & Johnson, AstraZeneca, SanBio and Athersys Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global acute ischemic stroke (AIS) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute ischemic stroke (AIS) market
Detailed Segmentation:
- Global Acute Ischemic Stroke (AIS) Market, By Therapeutics (Revenue, USD Bn, 2021 - 2033)
- Tissue Plasminogen Activator
- Anticoagulant
- Antiplatelet
- Antihypertensive
- Global Acute Ischemic Stroke (AIS) Market, By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Acute Ischemic Stroke (AIS) Market, By Region (Revenue, USD Bn, 2021 - 2033)
- North America
- By Therapeutics
- Tissue Plasminogen Activator
- Anticoagulant
- Antiplatelet
- Antihypertensive
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- U.S.
- Canada
- By Therapeutics
- Latin America
- By Therapeutics
- Tissue Plasminogen Activator
- Anticoagulant
- Antiplatelet
- Antihypertensive
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Therapeutics
- Europe
- By Therapeutics
- Tissue Plasminogen Activator
- Anticoagulant
- Antiplatelet
- Antihypertensive
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- By Therapeutics
- Asia Pacific
- By Therapeutics
- Tissue Plasminogen Activator
- Anticoagulant
- Antiplatelet
- Antihypertensive
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- By Therapeutics
- Middle East
- By Therapeutics
- Tissue Plasminogen Activator
- Anticoagulant
- Antiplatelet
- Antihypertensive
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- GCC
- Israel
- Rest of Middle East
- By Therapeutics
- Africa
- By Therapeutics
- Tissue Plasminogen Activator
- Anticoagulant
- Antiplatelet
- Antihypertensive
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region/Country
- South Africa
- Central Africa
- North Africa
- By Therapeutics
- Company Profiles
- Hoffmann-La Roche AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Boehringer Ingelheim
- Bayer AG
- Pfizer Inc.
- Biogen
- Daiichi Sankyo
- Bristol-Myers Squibb
- Johnson & Johnson
- AstraZeneca
- SanBio
- Athersys Inc.
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Therapeutics
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Recent Trends
- Product Launches and Approvals
- Mergers, Acquisitions, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
- PORTER's Analysis
4. Global Acute Ischemic Stroke (AIS) Market, By Therapeutics, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Tissue Plasminogen Activator
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Anticoagulant
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Antiplatelet
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Antihypertensive
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
5. Global Acute Ischemic Stroke (AIS) Market, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Hospitals Pharmacies
- Introduction
- Market Size and Forecast and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
6. Global Acute Ischemic Stroke (AIS) Market, By Region, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 -2033, (US$ Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 -2033, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 -2033, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 -2033, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 -2033, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutics, 2021 -2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 -2033, (US$ Bn)
- North Africa
- Central Africa
- South Africa
7. Competitive Landscape
- Company Profiles
- F. Hoffmann-La Roche Ltd
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Boehringer Ingelheim International GmbH
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Bayer AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Biogen
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- DAIICHI SANKYO COMPANY, LIMITED
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Bristol-Myers Squibb Company
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Johnson & Johnson Services, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- AstraZeneca
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- SanBio Co,Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Athersys, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Abbott
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Sanofi
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- ZZ Biotech
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Teva Pharmaceutical Industries Ltd
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Merck & Co., Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- NoNO Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- AliveCor, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Amgen Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Genentech USA, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- DiaMedica Therapeutics, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- F. Hoffmann-La Roche Ltd
8. Section
- References
- Research Methodology
- About us and Sales Contact
